Research forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. Report explains how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Don’t let your competitors get the head-start on you, order this report today.
Have you seen the recent news on Cancer Drugs?
- Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year
- Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes
- EU approval for Bayer’s prostate cancer drug
- Sanofi ditches late-stage bone marrow cancer drug
The Anti-cancer treatment market is already worth $77.4bn and continues to be one of the largest and fastest growing areas for new drug development – can you afford not to be involved? Should you and your company be capturing a greater market share?
Browse Full Research Report With TOC: http://www.radiantinsights.com/research/the-cancer-drugs-and-treatments-market
Essential facts examined in this report:
- Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.
- Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.
- Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.
Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this report.
Discover exactly what the industry leaders are doing TODAY -
In this report we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.
Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU
• Rituxan
• Herceptin
• Avastin
• Gleevec
• Revlimid
• Alimta
• Velcade
PLUS – In-depth country analysis – Discover which countries and regions will drive the oncology drugs market to 2023?
The US spent $322bn on healthcare in 2011, researcher estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.
But how will these country’s markets develop? This report will tell you - TODAY
As well as primary and secondary research sources, we interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketers and key clinical organizations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.
This report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug.
With over 240+ pages, and over 270+ charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceutical
Have you seen the recent news on Cancer Drugs?
- Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year
- Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes
- EU approval for Bayer’s prostate cancer drug
- Sanofi ditches late-stage bone marrow cancer drug
The Anti-cancer treatment market is already worth $77.4bn and continues to be one of the largest and fastest growing areas for new drug development – can you afford not to be involved? Should you and your company be capturing a greater market share?
Browse Full Research Report With TOC: http://www.radiantinsights.com/research/the-cancer-drugs-and-treatments-market
Essential facts examined in this report:
- Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.
- Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.
- Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.
Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this report.
Discover exactly what the industry leaders are doing TODAY -
In this report we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.
Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU
• Rituxan
• Herceptin
• Avastin
• Gleevec
• Revlimid
• Alimta
• Velcade
PLUS – In-depth country analysis – Discover which countries and regions will drive the oncology drugs market to 2023?
The US spent $322bn on healthcare in 2011, researcher estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.
But how will these country’s markets develop? This report will tell you - TODAY
As well as primary and secondary research sources, we interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketers and key clinical organizations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.
This report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug.
With over 240+ pages, and over 270+ charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceutical
No comments:
Post a Comment